Literature DB >> 19816064

TAM receptor signalling and demyelination.

Michele D Binder1, Trevor J Kilpatrick.   

Abstract

The TAM family (Tyro3, Axl and Mer) of receptor protein tyrosine kinases play pivotal roles in a number of major cellular processes: cell survival and proliferation, immunomodulation and phagocytosis. These processes are central to both the initial development and pathological course of human multiple sclerosis. All three receptors and their ligands, Gas6 (growth arrest-specific gene 6) and protein S, are expressed in the central nervous system (CNS), including in oligodendrocytes, the myelin-producing cell of the CNS. Recent studies have shown that Gas6-dependent TAM receptor signalling is an important modulator of oligodendrocyte survival and microglial phenotype both in vitro and in vivo. Multiple lines of evidence allow us to hypothesise that, during a demyelinating challenge, dysfunctional TAM receptor signalling could lead to a 'vicious cycle' of cell death, reduced phagocytosis and deleterious immune hyper-activation. A current challenge in this field is to expand our understanding of TAM receptor signalling from rodent models of central demyelination to human disease. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816064     DOI: 10.1159/000231894

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  16 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

3.  Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays.

Authors:  Gregory Costain; Anath C Lionel; Daniele Merico; Pamela Forsythe; Kathryn Russell; Chelsea Lowther; Tracy Yuen; Janice Husted; Dimitri J Stavropoulos; Marsha Speevak; Eva W C Chow; Christian R Marshall; Stephen W Scherer; Anne S Bassett
Journal:  Hum Mol Genet       Date:  2013-06-27       Impact factor: 6.150

4.  The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus.

Authors:  Catherine L Hunt; Andrey A Kolokoltsov; Robert A Davey; Wendy Maury
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 5.  Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy.

Authors:  Abbas Mirshafiey; Ghasem Ghalamfarsa; Babak Asghari; Gholamreza Azizi
Journal:  Innov Clin Neurosci       Date:  2014-07

Review 6.  TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system.

Authors:  Angela M Pierce; Amy K Keating
Journal:  Brain Res       Date:  2013-11-01       Impact factor: 3.252

7.  Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.

Authors:  Jessica E Brown; Meredith Krodel; Mauricio Pazos; Cary Lai; Anne L Prieto
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

8.  Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.

Authors:  Gerry Z M Ma; Jim Stankovich; Trevor J Kilpatrick; Michele D Binder; Judith Field
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

9.  Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation.

Authors:  Laura Facci; Massimo Barbierato; Mariella Fusco; Pietro Giusti; Morena Zusso
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

10.  Growth arrest specific gene 6 protein concentration in cerebrospinal fluid correlates with relapse severity in multiple sclerosis.

Authors:  P P Sainaghi; L Collimedaglia; F Alciato; R Molinari; D Sola; E Ranza; P Naldi; F Monaco; M Leone; M Pirisi; G C Avanzi
Journal:  Mediators Inflamm       Date:  2013-05-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.